Table 4.
Univariate and multivariate analyses of the relationship of CD44+/CD24-/low tumor cells to overall survival
| Variable |
Univariate analysis |
Multivariate analysis |
||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p-value | HR | 95% CI | p-value | |
| CD44+/CD24-/low tumor cells | ||||||
| High |
2.193 |
1.383-3.477 |
0.001 |
2.237 |
1.345-3.720 |
0.002 |
| Low |
1.000 |
|
|
1.000 |
|
|
| ER status | ||||||
| Positive |
0.757 |
0.488-1.175 |
0.215 |
1.164 |
0.585-2.314 |
0.665 |
| Negative |
1.000 |
|
|
1.000 |
|
|
| PR status | ||||||
| Positive |
0.702 |
0.457–1.078 |
0.106 |
0.968 |
0.496–1.888 |
0.924 |
| Negative |
1.000 |
|
|
1.000 |
|
|
| Her2 status | ||||||
| Positive |
0.932 |
0.605–1.435 |
0.748 |
1.583 |
0.782–3.201 |
0.201 |
| Negative |
1.000 |
|
|
1.000 |
|
|
| Basal-like feature* | ||||||
| Present |
0.608 |
0.389-0.949 |
0.029 |
0.342 |
0.131-0.891 |
0.028 |
| Absent |
1.000 |
|
|
1.000 |
|
|
| TNM stage | ||||||
| Stage III/IV |
1.614 |
1.055–2.470 |
0.027 |
1.652 |
1.014–2.690 |
0.044 |
| Stage I/II |
1.000 |
|
|
1.000 |
|
|
| Lymph node involvement | ||||||
| Absent |
0.891 |
0.528-1.504 |
0.666 |
0.674 |
0.343-1.323 |
0.251 |
| Present |
1.000 |
|
|
1.000 |
|
|
| Age (years) | ||||||
| ≥ 50 |
1.110 |
0.735–1.676 |
0.621 |
1.384 |
0.847–2.260 |
0.194 |
| < 50 | 1.000 | 1.000 | ||||
Abbreviations: HR, hazard ratio estimated from Cox proportional hazard regression model; CI, confidence interval of the estimated HR. ER, estrogen receptor; PR, progesterone receptor; Her2, human epidermal growth factor receptor 2.
* Immunohistochemically negative for both SR and Her2.